Device Trial Radar · NCT04488159
Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer
Last checked: Nov 20, 2026Latest source record: Sep 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Dec 1, 2024
Primary completion
Dec 1, 2025
Study completion Jun 1, 2026
Sponsor
- Lead sponsor
- Johannes Laengle, MD, PhDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall aim of this study is to prospectively validate the superiority of the Immunoscore as a decision guidance for adjuvant chemotherapy in stage III colon cancer patients, in comparison to the conventional TNM-based high- or low-risk classification.
Conditions
- Colon Cancer Stage III
Interventions
CapecitabineDrug
Tablet
OxaliplatinDrug
Infusion
FluorouracilDrug
Infusion
LeucovorinDrug
Infusion
Immunoscore® assayDevice
Whole-slide tissue analysis of CD3+ and cytotoxic CD8+ T cells in the tumor and in the invasive margin
Physical exerciseOther
Increasing stair walking exercise twice a week over 12 weeks total.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free survival (DFS)Time frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical University of Vienna
Vienna, State of Vienna, Austria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.